Compare GIC & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIC | ODTX |
|---|---|---|
| Founded | 1949 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1996 | 2025 |
| Metric | GIC | ODTX |
|---|---|---|
| Price | $39.60 | $24.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 119.1K | ★ 132.5K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | ★ 17.09 | N/A |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $1,379,100,000.00 | N/A |
| Revenue This Year | $5.72 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | $28.71 | ★ N/A |
| Revenue Growth | ★ 4.80 | N/A |
| 52 Week Low | $26.40 | $15.10 |
| 52 Week High | $40.71 | $28.00 |
| Indicator | GIC | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.34 | 65.79 |
| Support Level | $38.16 | $19.84 |
| Resistance Level | $40.71 | $28.00 |
| Average True Range (ATR) | 0.89 | 1.92 |
| MACD | -0.12 | 0.30 |
| Stochastic Oscillator | 62.72 | 71.87 |
Global Industrial Co is a value-added industrial distributor. The company distributes a wide range of industrial and maintenance, repair, and operations (MRO) products to customers across North America, including storage and shelving, safety and security, carts and trucks, HVAC and fans, furniture and decor, material handling, janitorial and facility maintenance, workbenches and shop desks, tools and instruments, plumbing and pumps, office and school supplies, packaging and shipping, lighting and electrical, food service and retail, medical and laboratory, motors and power transmission, building supplies, machining, fasteners and hardware, vehicle maintenance, and raw material.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.